Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation

M. H. Al'Halawani, Jennifer Lynn Larsen, S. Miller, K. Frisbie, R. J. Taylor, R. J. Stratta

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hyperlipidemia is a significant risk factor for atherosclerotic vascular disease. We have shown previously that pancreas transplantation (PTX) improves but does not normalize lipids in most PTX recipients. We studied whether pravastatin was effective in treating 10 patients with elevated low density lipoprotein (LDL)-cholesterol (LDL-C) following PTX. Seven men and 3 women were studied. Six received combined kid-ney-pancreas transplantations, while 4 received PTX alone. Age at time of PTX was 37.2±2.2 years (mean ± SEM), and 4 had established coronary artery disease before PTX. Mean cholesterol (C), LDL-C, triglycerides (TG), and high density lipoprotein (HDL)-cholesterol (HDL-C) were 236±12, 142+6, 222±50, and 49±4 mg/dl before PTX. The LDL to HDL ratio was 3.0 ±0.3. After PTX, excluding the first 45 days, mean C, LDL-C, and HDL-C increased to 278±10,178±7, and 63±6 mg/dl (all P≤O.Oδ), respectively. TG, LDL to HDL ratio, and weight were unchanged. Pravastatin (11.7±0.8 mg/day, mean ± SEM) was initiated 250±53 days after PTX. During therapy, C and LDL-C decreased on average to 231±10 and 134±8 mg/dl, respectively (both P<0.01), while HDL did not change. The decreases in C and LDL-C were unexplained by a decrease in weight, cyclosporine dose or concentration, or increase in serum creatinine. However, prednisone dose decreased over the same interval, so a contribution from this variable cannot be excluded. No evidence of toxicity was identified during therapy. This is one of the first reports demonstrating that pravastatin is a safe and effective treatment for elevated C and LDL-C in patients following PTX. However, pravastatin did not increase HDL or decrease TG, as observed in the nontransplantation setting. Whether pravastatin or any hypolipidemia therapy can prevent cardiovascular events or mortality following PTX remains to be established.

Original languageEnglish (US)
Pages (from-to)1204-1209
Number of pages6
JournalTransplantation
Volume58
Issue number12
StatePublished - Dec 15 1994

Fingerprint

Pravastatin
Pancreas Transplantation
HDL Lipoproteins
LDL Lipoproteins
LDL Cholesterol
Serum
Weights and Measures
Therapeutics
Prednisone
Hyperlipidemias
Vascular Diseases
HDL Cholesterol
Cyclosporine
Coronary Artery Disease
Creatinine
Triglycerides
Cholesterol
Lipids
Mortality

ASJC Scopus subject areas

  • Transplantation

Cite this

Al'Halawani, M. H., Larsen, J. L., Miller, S., Frisbie, K., Taylor, R. J., & Stratta, R. J. (1994). Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation. Transplantation, 58(12), 1204-1209.

Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation. / Al'Halawani, M. H.; Larsen, Jennifer Lynn; Miller, S.; Frisbie, K.; Taylor, R. J.; Stratta, R. J.

In: Transplantation, Vol. 58, No. 12, 15.12.1994, p. 1204-1209.

Research output: Contribution to journalArticle

Al'Halawani, MH, Larsen, JL, Miller, S, Frisbie, K, Taylor, RJ & Stratta, RJ 1994, 'Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation', Transplantation, vol. 58, no. 12, pp. 1204-1209.
Al'Halawani, M. H. ; Larsen, Jennifer Lynn ; Miller, S. ; Frisbie, K. ; Taylor, R. J. ; Stratta, R. J. / Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation. In: Transplantation. 1994 ; Vol. 58, No. 12. pp. 1204-1209.
@article{779fcc0d9b06433d9401d1ed7527e74c,
title = "Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation",
abstract = "Hyperlipidemia is a significant risk factor for atherosclerotic vascular disease. We have shown previously that pancreas transplantation (PTX) improves but does not normalize lipids in most PTX recipients. We studied whether pravastatin was effective in treating 10 patients with elevated low density lipoprotein (LDL)-cholesterol (LDL-C) following PTX. Seven men and 3 women were studied. Six received combined kid-ney-pancreas transplantations, while 4 received PTX alone. Age at time of PTX was 37.2±2.2 years (mean ± SEM), and 4 had established coronary artery disease before PTX. Mean cholesterol (C), LDL-C, triglycerides (TG), and high density lipoprotein (HDL)-cholesterol (HDL-C) were 236±12, 142+6, 222±50, and 49±4 mg/dl before PTX. The LDL to HDL ratio was 3.0 ±0.3. After PTX, excluding the first 45 days, mean C, LDL-C, and HDL-C increased to 278±10,178±7, and 63±6 mg/dl (all P≤O.Oδ), respectively. TG, LDL to HDL ratio, and weight were unchanged. Pravastatin (11.7±0.8 mg/day, mean ± SEM) was initiated 250±53 days after PTX. During therapy, C and LDL-C decreased on average to 231±10 and 134±8 mg/dl, respectively (both P<0.01), while HDL did not change. The decreases in C and LDL-C were unexplained by a decrease in weight, cyclosporine dose or concentration, or increase in serum creatinine. However, prednisone dose decreased over the same interval, so a contribution from this variable cannot be excluded. No evidence of toxicity was identified during therapy. This is one of the first reports demonstrating that pravastatin is a safe and effective treatment for elevated C and LDL-C in patients following PTX. However, pravastatin did not increase HDL or decrease TG, as observed in the nontransplantation setting. Whether pravastatin or any hypolipidemia therapy can prevent cardiovascular events or mortality following PTX remains to be established.",
author = "Al'Halawani, {M. H.} and Larsen, {Jennifer Lynn} and S. Miller and K. Frisbie and Taylor, {R. J.} and Stratta, {R. J.}",
year = "1994",
month = "12",
day = "15",
language = "English (US)",
volume = "58",
pages = "1204--1209",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation

AU - Al'Halawani, M. H.

AU - Larsen, Jennifer Lynn

AU - Miller, S.

AU - Frisbie, K.

AU - Taylor, R. J.

AU - Stratta, R. J.

PY - 1994/12/15

Y1 - 1994/12/15

N2 - Hyperlipidemia is a significant risk factor for atherosclerotic vascular disease. We have shown previously that pancreas transplantation (PTX) improves but does not normalize lipids in most PTX recipients. We studied whether pravastatin was effective in treating 10 patients with elevated low density lipoprotein (LDL)-cholesterol (LDL-C) following PTX. Seven men and 3 women were studied. Six received combined kid-ney-pancreas transplantations, while 4 received PTX alone. Age at time of PTX was 37.2±2.2 years (mean ± SEM), and 4 had established coronary artery disease before PTX. Mean cholesterol (C), LDL-C, triglycerides (TG), and high density lipoprotein (HDL)-cholesterol (HDL-C) were 236±12, 142+6, 222±50, and 49±4 mg/dl before PTX. The LDL to HDL ratio was 3.0 ±0.3. After PTX, excluding the first 45 days, mean C, LDL-C, and HDL-C increased to 278±10,178±7, and 63±6 mg/dl (all P≤O.Oδ), respectively. TG, LDL to HDL ratio, and weight were unchanged. Pravastatin (11.7±0.8 mg/day, mean ± SEM) was initiated 250±53 days after PTX. During therapy, C and LDL-C decreased on average to 231±10 and 134±8 mg/dl, respectively (both P<0.01), while HDL did not change. The decreases in C and LDL-C were unexplained by a decrease in weight, cyclosporine dose or concentration, or increase in serum creatinine. However, prednisone dose decreased over the same interval, so a contribution from this variable cannot be excluded. No evidence of toxicity was identified during therapy. This is one of the first reports demonstrating that pravastatin is a safe and effective treatment for elevated C and LDL-C in patients following PTX. However, pravastatin did not increase HDL or decrease TG, as observed in the nontransplantation setting. Whether pravastatin or any hypolipidemia therapy can prevent cardiovascular events or mortality following PTX remains to be established.

AB - Hyperlipidemia is a significant risk factor for atherosclerotic vascular disease. We have shown previously that pancreas transplantation (PTX) improves but does not normalize lipids in most PTX recipients. We studied whether pravastatin was effective in treating 10 patients with elevated low density lipoprotein (LDL)-cholesterol (LDL-C) following PTX. Seven men and 3 women were studied. Six received combined kid-ney-pancreas transplantations, while 4 received PTX alone. Age at time of PTX was 37.2±2.2 years (mean ± SEM), and 4 had established coronary artery disease before PTX. Mean cholesterol (C), LDL-C, triglycerides (TG), and high density lipoprotein (HDL)-cholesterol (HDL-C) were 236±12, 142+6, 222±50, and 49±4 mg/dl before PTX. The LDL to HDL ratio was 3.0 ±0.3. After PTX, excluding the first 45 days, mean C, LDL-C, and HDL-C increased to 278±10,178±7, and 63±6 mg/dl (all P≤O.Oδ), respectively. TG, LDL to HDL ratio, and weight were unchanged. Pravastatin (11.7±0.8 mg/day, mean ± SEM) was initiated 250±53 days after PTX. During therapy, C and LDL-C decreased on average to 231±10 and 134±8 mg/dl, respectively (both P<0.01), while HDL did not change. The decreases in C and LDL-C were unexplained by a decrease in weight, cyclosporine dose or concentration, or increase in serum creatinine. However, prednisone dose decreased over the same interval, so a contribution from this variable cannot be excluded. No evidence of toxicity was identified during therapy. This is one of the first reports demonstrating that pravastatin is a safe and effective treatment for elevated C and LDL-C in patients following PTX. However, pravastatin did not increase HDL or decrease TG, as observed in the nontransplantation setting. Whether pravastatin or any hypolipidemia therapy can prevent cardiovascular events or mortality following PTX remains to be established.

UR - http://www.scopus.com/inward/record.url?scp=0028584186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028584186&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 1204

EP - 1209

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 12

ER -